FIELD: medicine.
SUBSTANCE: invention concerns the criteria for the diagnosis of the toxic effect of silver nanoparticles encapsulated in the natural polymeric matrix of arabinogalactan (nAgAG). Laboratory animals of the experimental group for 9 days intragastrically injected aqueous solution of nAgAg at a rate of 100 mcg of silver per kilogram of weight in 0.5 ml of distilled water. The animals of the control group receive 0.5 ml of distilled water for 9 days intragastrically. Immediately after the end of the exposure, sections of the brain tissues of the animals of both groups are made. They are stained for antibodies to the proteins caspase-3 and bcl-2 and conduct a survey microscopy of the preparations obtained. At this time, the total number of cells in 0.2 mm2, the number of pathologically altered neurons with caspase 3 expression, the number of pathologically altered neurons with bcl-2 expression, the number of normal neurons with caspase 3 expression, the number of normal neurons with bcl-2 expression as a percentage of the total cell count of 0.2 mm2. The ratio is calculated of these indicators on the drugs of the experimental group to those of the control group. When the number of pathologically altered neurons with caspase 3 expression increased by an average of 1.6 times in the experimental group, the number of normal neurons with the expression of caspase 3 averaged 2.5 times, pathologically altered neurons with bcl-2 expression on average of 2.4 fold, the number of normal neurons expressing bcl-2 is 1.5 times the conclusion about the presence of the process of apoptosis in the brain tissues of animals.
EFFECT: method makes it possible to evaluate the functional state of neurons of the brain under the influence of silver nanobiocomposites, expands the arsenal of methods for evaluating the effect of toxic substances on the organism of laboratory animals.
1 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF EVALUATING TOXIC EFFECTS OF SILVER NANOPARTICLES ENCAPSULATED WITHIN POLYMER MATRIX OF ARABINOGALACTAN ON BRAIN TISSUE OF LABORATORY ANIMALS IN LONG-TERM | 2015 |
|
RU2578545C1 |
METHOD OF ASSESSING THE TOXIC EFFECT OF A BIMETALLIC FERRUM-GADOLINIUM NANOCOMPOSITE ENCAPSULATED IN A NATURAL POLYMER MATRIX OF ARABINOGALACTAN ON LABORATORY ANIMALS | 2019 |
|
RU2733504C1 |
METHOD FOR ESTIMATING THE TOXICITY OF MICRO- AND NANOPARTICLES BY THE MORPHOLOGICAL FEATURES THEREOF | 2020 |
|
RU2756524C1 |
AGENT WITH ANTIAPOPTOTIC ACTIVITY | 2018 |
|
RU2685428C1 |
METHOD FOR ASSESSING COPPER NANOPARTICLES ADMINISTRATION SAFETY | 2011 |
|
RU2477485C2 |
DIAGNOSTIC TECHNIQUE FOR MERCURY ENCEPHALOPATHY IN SMALL LABORATORY ANIMALS | 2011 |
|
RU2471247C1 |
AGENT WITH ANTITUMOR ACTIVITY BASED ON ARABINOGALACTAN NANOCOMPOSITES WITH SELENIUM AND METHODS FOR PREPARIATION OF SUCH NANOBIOCOMPOSITES | 2015 |
|
RU2614363C2 |
METHOD OF TREATING PATIENTS WITH CHRONIC ALCOHOL INTOXICATION | 2014 |
|
RU2566075C1 |
HEPATOPROTECTIVE AND ANTIOXIDANT DRUG FOR ANIMALS BASED ON AQUEOUS SOLUTION OF FULLERENE C, RESVERATROL AND BETAINE HYDROCHLORIDE | 2020 |
|
RU2770534C1 |
APPLICATION OF (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINES IN DEMENTIA AND PARKINSON'S DISEASE TREATMENT | 2003 |
|
RU2332218C2 |
Authors
Dates
2017-05-31—Published
2016-04-25—Filed